Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial
In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing drug, gene, and cumulative interaction risk may provide valuable insights in prescription drug treatment, reducing re-hospitalization and emer...
Saved in:
| Published in | PloS one Vol. 12; no. 2; p. e0170905 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
02.02.2017
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0170905 |
Cover
| Abstract | In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing drug, gene, and cumulative interaction risk may provide valuable insights in prescription drug treatment, reducing re-hospitalization and emergency department (ED) visits. We assessed the clinical impact of pharmacogenetic profiling integrating binary and cumulative drug and gene interaction warnings on home health polypharmacy patients.
This prospective, open-label, randomized controlled trial was conducted at one hospital-based home health agency between February 2015 and February 2016. Recruitment came from patient referrals to home health at hospital discharge. Eligible patients were aged 50 years and older and taking or initiating treatment with medications with potential or significant drug-gene-based interactions. Subjects (n = 110) were randomized to pharmacogenetic profiling (n = 57). The study pharmacist reviewed drug-drug, drug-gene, and cumulative drug and/or gene interactions using the YouScript® CDST to provide drug therapy recommendations to clinicians. The control group (n = 53) received treatment as usual including pharmacist guided medication management using a standard drug information resource. The primary outcome measure was the number of re-hospitalizations and ED visits at 30 and 60 days after discharge from the hospital. The mean number of re-hospitalizations per patient in the tested vs. untested group was 0.25 vs. 0.38 at 30 days (relative risk (RR), 0.65; 95% confidence interval (CI), 0.32-1.28; P = 0.21) and 0.33 vs. 0.70 at 60 days following enrollment (RR, 0.48; 95% CI, 0.27-0.82; P = 0.007). The mean number of ED visits per patient in the tested vs. untested group was 0.25 vs. 0.40 at 30 days (RR, 0.62; 95% CI, 0.31-1.21; P = 0.16) and 0.39 vs. 0.66 at 60 days (RR, 0.58; 95% CI, 0.34-0.99; P = 0.045). Differences in composite outcomes at 60 days (exploratory endpoints) were also found. Of the total 124 drug therapy recommendations passed on to clinicians, 96 (77%) were followed. These findings should be verified with additional prospective confirmatory studies involving real-world applications in larger populations to broaden acceptance in routine clinical practice.
Pharmacogenetic testing of polypharmacy patients aged 50 and older, supported by an appropriate CDST, considerably reduced re-hospitalizations and ED visits at 60 days following enrollment resulting in potential health resource utilization savings and improved healthcare.
ClinicalTrials.gov NCT02378220. |
|---|---|
| AbstractList | In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing drug, gene, and cumulative interaction risk may provide valuable insights in prescription drug treatment, reducing re-hospitalization and emergency department (ED) visits. We assessed the clinical impact of pharmacogenetic profiling integrating binary and cumulative drug and gene interaction warnings on home health polypharmacy patients.
This prospective, open-label, randomized controlled trial was conducted at one hospital-based home health agency between February 2015 and February 2016. Recruitment came from patient referrals to home health at hospital discharge. Eligible patients were aged 50 years and older and taking or initiating treatment with medications with potential or significant drug-gene-based interactions. Subjects (n = 110) were randomized to pharmacogenetic profiling (n = 57). The study pharmacist reviewed drug-drug, drug-gene, and cumulative drug and/or gene interactions using the YouScript® CDST to provide drug therapy recommendations to clinicians. The control group (n = 53) received treatment as usual including pharmacist guided medication management using a standard drug information resource. The primary outcome measure was the number of re-hospitalizations and ED visits at 30 and 60 days after discharge from the hospital. The mean number of re-hospitalizations per patient in the tested vs. untested group was 0.25 vs. 0.38 at 30 days (relative risk (RR), 0.65; 95% confidence interval (CI), 0.32-1.28; P = 0.21) and 0.33 vs. 0.70 at 60 days following enrollment (RR, 0.48; 95% CI, 0.27-0.82; P = 0.007). The mean number of ED visits per patient in the tested vs. untested group was 0.25 vs. 0.40 at 30 days (RR, 0.62; 95% CI, 0.31-1.21; P = 0.16) and 0.39 vs. 0.66 at 60 days (RR, 0.58; 95% CI, 0.34-0.99; P = 0.045). Differences in composite outcomes at 60 days (exploratory endpoints) were also found. Of the total 124 drug therapy recommendations passed on to clinicians, 96 (77%) were followed. These findings should be verified with additional prospective confirmatory studies involving real-world applications in larger populations to broaden acceptance in routine clinical practice.
Pharmacogenetic testing of polypharmacy patients aged 50 and older, supported by an appropriate CDST, considerably reduced re-hospitalizations and ED visits at 60 days following enrollment resulting in potential health resource utilization savings and improved healthcare.
ClinicalTrials.gov NCT02378220. Background In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing drug, gene, and cumulative interaction risk may provide valuable insights in prescription drug treatment, reducing re-hospitalization and emergency department (ED) visits. We assessed the clinical impact of pharmacogenetic profiling integrating binary and cumulative drug and gene interaction warnings on home health polypharmacy patients. Methods and findings This prospective, open-label, randomized controlled trial was conducted at one hospital-based home health agency between February 2015 and February 2016. Recruitment came from patient referrals to home health at hospital discharge. Eligible patients were aged 50 years and older and taking or initiating treatment with medications with potential or significant drug-gene-based interactions. Subjects (n = 110) were randomized to pharmacogenetic profiling (n = 57). The study pharmacist reviewed drug-drug, drug-gene, and cumulative drug and/or gene interactions using the YouScript ® CDST to provide drug therapy recommendations to clinicians. The control group (n = 53) received treatment as usual including pharmacist guided medication management using a standard drug information resource. The primary outcome measure was the number of re-hospitalizations and ED visits at 30 and 60 days after discharge from the hospital. The mean number of re-hospitalizations per patient in the tested vs. untested group was 0.25 vs. 0.38 at 30 days (relative risk (RR), 0.65; 95% confidence interval (CI), 0.32–1.28; P = 0.21) and 0.33 vs. 0.70 at 60 days following enrollment (RR, 0.48; 95% CI, 0.27–0.82; P = 0.007). The mean number of ED visits per patient in the tested vs. untested group was 0.25 vs. 0.40 at 30 days (RR, 0.62; 95% CI, 0.31–1.21; P = 0.16) and 0.39 vs. 0.66 at 60 days (RR, 0.58; 95% CI, 0.34–0.99; P = 0.045). Differences in composite outcomes at 60 days (exploratory endpoints) were also found. Of the total 124 drug therapy recommendations passed on to clinicians, 96 (77%) were followed. These findings should be verified with additional prospective confirmatory studies involving real-world applications in larger populations to broaden acceptance in routine clinical practice. Conclusions Pharmacogenetic testing of polypharmacy patients aged 50 and older, supported by an appropriate CDST, considerably reduced re-hospitalizations and ED visits at 60 days following enrollment resulting in potential health resource utilization savings and improved healthcare. Trial registration ClinicalTrials.gov NCT02378220 Background In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing drug, gene, and cumulative interaction risk may provide valuable insights in prescription drug treatment, reducing re-hospitalization and emergency department (ED) visits. We assessed the clinical impact of pharmacogenetic profiling integrating binary and cumulative drug and gene interaction warnings on home health polypharmacy patients. Methods and findings This prospective, open-label, randomized controlled trial was conducted at one hospital-based home health agency between February 2015 and February 2016. Recruitment came from patient referrals to home health at hospital discharge. Eligible patients were aged 50 years and older and taking or initiating treatment with medications with potential or significant drug-gene-based interactions. Subjects (n = 110) were randomized to pharmacogenetic profiling (n = 57). The study pharmacist reviewed drug-drug, drug-gene, and cumulative drug and/or gene interactions using the YouScript.sup.® CDST to provide drug therapy recommendations to clinicians. The control group (n = 53) received treatment as usual including pharmacist guided medication management using a standard drug information resource. The primary outcome measure was the number of re-hospitalizations and ED visits at 30 and 60 days after discharge from the hospital. The mean number of re-hospitalizations per patient in the tested vs. untested group was 0.25 vs. 0.38 at 30 days (relative risk (RR), 0.65; 95% confidence interval (CI), 0.32-1.28; P = 0.21) and 0.33 vs. 0.70 at 60 days following enrollment (RR, 0.48; 95% CI, 0.27-0.82; P = 0.007). The mean number of ED visits per patient in the tested vs. untested group was 0.25 vs. 0.40 at 30 days (RR, 0.62; 95% CI, 0.31-1.21; P = 0.16) and 0.39 vs. 0.66 at 60 days (RR, 0.58; 95% CI, 0.34-0.99; P = 0.045). Differences in composite outcomes at 60 days (exploratory endpoints) were also found. Of the total 124 drug therapy recommendations passed on to clinicians, 96 (77%) were followed. These findings should be verified with additional prospective confirmatory studies involving real-world applications in larger populations to broaden acceptance in routine clinical practice. Conclusions Pharmacogenetic testing of polypharmacy patients aged 50 and older, supported by an appropriate CDST, considerably reduced re-hospitalizations and ED visits at 60 days following enrollment resulting in potential health resource utilization savings and improved healthcare. Trial registration ClinicalTrials.gov NCT02378220 In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing drug, gene, and cumulative interaction risk may provide valuable insights in prescription drug treatment, reducing re-hospitalization and emergency department (ED) visits. We assessed the clinical impact of pharmacogenetic profiling integrating binary and cumulative drug and gene interaction warnings on home health polypharmacy patients. This prospective, open-label, randomized controlled trial was conducted at one hospital-based home health agency between February 2015 and February 2016. Recruitment came from patient referrals to home health at hospital discharge. Eligible patients were aged 50 years and older and taking or initiating treatment with medications with potential or significant drug-gene-based interactions. Subjects (n = 110) were randomized to pharmacogenetic profiling (n = 57). The study pharmacist reviewed drug-drug, drug-gene, and cumulative drug and/or gene interactions using the YouScript.sup.® CDST to provide drug therapy recommendations to clinicians. The control group (n = 53) received treatment as usual including pharmacist guided medication management using a standard drug information resource. The primary outcome measure was the number of re-hospitalizations and ED visits at 30 and 60 days after discharge from the hospital. Pharmacogenetic testing of polypharmacy patients aged 50 and older, supported by an appropriate CDST, considerably reduced re-hospitalizations and ED visits at 60 days following enrollment resulting in potential health resource utilization savings and improved healthcare. Background In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing drug, gene, and cumulative interaction risk may provide valuable insights in prescription drug treatment, reducing re-hospitalization and emergency department (ED) visits. We assessed the clinical impact of pharmacogenetic profiling integrating binary and cumulative drug and gene interaction warnings on home health polypharmacy patients. Methods and findings This prospective, open-label, randomized controlled trial was conducted at one hospital-based home health agency between February 2015 and February 2016. Recruitment came from patient referrals to home health at hospital discharge. Eligible patients were aged 50 years and older and taking or initiating treatment with medications with potential or significant drug-gene-based interactions. Subjects (n = 110) were randomized to pharmacogenetic profiling (n = 57). The study pharmacist reviewed drug-drug, drug-gene, and cumulative drug and/or gene interactions using the YouScript registered CDST to provide drug therapy recommendations to clinicians. The control group (n = 53) received treatment as usual including pharmacist guided medication management using a standard drug information resource. The primary outcome measure was the number of re-hospitalizations and ED visits at 30 and 60 days after discharge from the hospital. The mean number of re-hospitalizations per patient in the tested vs. untested group was 0.25 vs. 0.38 at 30 days (relative risk (RR), 0.65; 95% confidence interval (CI), 0.32-1.28; P = 0.21) and 0.33 vs. 0.70 at 60 days following enrollment (RR, 0.48; 95% CI, 0.27-0.82; P = 0.007). The mean number of ED visits per patient in the tested vs. untested group was 0.25 vs. 0.40 at 30 days (RR, 0.62; 95% CI, 0.31-1.21; P = 0.16) and 0.39 vs. 0.66 at 60 days (RR, 0.58; 95% CI, 0.34-0.99; P = 0.045). Differences in composite outcomes at 60 days (exploratory endpoints) were also found. Of the total 124 drug therapy recommendations passed on to clinicians, 96 (77%) were followed. These findings should be verified with additional prospective confirmatory studies involving real-world applications in larger populations to broaden acceptance in routine clinical practice. Conclusions Pharmacogenetic testing of polypharmacy patients aged 50 and older, supported by an appropriate CDST, considerably reduced re-hospitalizations and ED visits at 60 days following enrollment resulting in potential health resource utilization savings and improved healthcare. Trial registration ClinicalTrials.gov NCT02378220 Background In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing drug, gene, and cumulative interaction risk may provide valuable insights in prescription drug treatment, reducing re-hospitalization and emergency department (ED) visits. We assessed the clinical impact of pharmacogenetic profiling integrating binary and cumulative drug and gene interaction warnings on home health polypharmacy patients. Methods and findings This prospective, open-label, randomized controlled trial was conducted at one hospital-based home health agency between February 2015 and February 2016. Recruitment came from patient referrals to home health at hospital discharge. Eligible patients were aged 50 years and older and taking or initiating treatment with medications with potential or significant drug-gene-based interactions. Subjects (n = 110) were randomized to pharmacogenetic profiling (n = 57). The study pharmacist reviewed drug-drug, drug-gene, and cumulative drug and/or gene interactions using the YouScript® CDST to provide drug therapy recommendations to clinicians. The control group (n = 53) received treatment as usual including pharmacist guided medication management using a standard drug information resource. The primary outcome measure was the number of re-hospitalizations and ED visits at 30 and 60 days after discharge from the hospital. The mean number of re-hospitalizations per patient in the tested vs. untested group was 0.25 vs. 0.38 at 30 days (relative risk (RR), 0.65; 95% confidence interval (CI), 0.32–1.28; P = 0.21) and 0.33 vs. 0.70 at 60 days following enrollment (RR, 0.48; 95% CI, 0.27–0.82; P = 0.007). The mean number of ED visits per patient in the tested vs. untested group was 0.25 vs. 0.40 at 30 days (RR, 0.62; 95% CI, 0.31–1.21; P = 0.16) and 0.39 vs. 0.66 at 60 days (RR, 0.58; 95% CI, 0.34–0.99; P = 0.045). Differences in composite outcomes at 60 days (exploratory endpoints) were also found. Of the total 124 drug therapy recommendations passed on to clinicians, 96 (77%) were followed. These findings should be verified with additional prospective confirmatory studies involving real-world applications in larger populations to broaden acceptance in routine clinical practice. Conclusions Pharmacogenetic testing of polypharmacy patients aged 50 and older, supported by an appropriate CDST, considerably reduced re-hospitalizations and ED visits at 60 days following enrollment resulting in potential health resource utilization savings and improved healthcare. Trial registration ClinicalTrials.gov NCT02378220 BackgroundIn polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing drug, gene, and cumulative interaction risk may provide valuable insights in prescription drug treatment, reducing re-hospitalization and emergency department (ED) visits. We assessed the clinical impact of pharmacogenetic profiling integrating binary and cumulative drug and gene interaction warnings on home health polypharmacy patients.Methods and findingsThis prospective, open-label, randomized controlled trial was conducted at one hospital-based home health agency between February 2015 and February 2016. Recruitment came from patient referrals to home health at hospital discharge. Eligible patients were aged 50 years and older and taking or initiating treatment with medications with potential or significant drug-gene-based interactions. Subjects (n = 110) were randomized to pharmacogenetic profiling (n = 57). The study pharmacist reviewed drug-drug, drug-gene, and cumulative drug and/or gene interactions using the YouScript® CDST to provide drug therapy recommendations to clinicians. The control group (n = 53) received treatment as usual including pharmacist guided medication management using a standard drug information resource. The primary outcome measure was the number of re-hospitalizations and ED visits at 30 and 60 days after discharge from the hospital. The mean number of re-hospitalizations per patient in the tested vs. untested group was 0.25 vs. 0.38 at 30 days (relative risk (RR), 0.65; 95% confidence interval (CI), 0.32-1.28; P = 0.21) and 0.33 vs. 0.70 at 60 days following enrollment (RR, 0.48; 95% CI, 0.27-0.82; P = 0.007). The mean number of ED visits per patient in the tested vs. untested group was 0.25 vs. 0.40 at 30 days (RR, 0.62; 95% CI, 0.31-1.21; P = 0.16) and 0.39 vs. 0.66 at 60 days (RR, 0.58; 95% CI, 0.34-0.99; P = 0.045). Differences in composite outcomes at 60 days (exploratory endpoints) were also found. Of the total 124 drug therapy recommendations passed on to clinicians, 96 (77%) were followed. These findings should be verified with additional prospective confirmatory studies involving real-world applications in larger populations to broaden acceptance in routine clinical practice.ConclusionsPharmacogenetic testing of polypharmacy patients aged 50 and older, supported by an appropriate CDST, considerably reduced re-hospitalizations and ED visits at 60 days following enrollment resulting in potential health resource utilization savings and improved healthcare.Trial registrationClinicalTrials.gov NCT02378220. |
| Audience | Academic |
| Author | Thirumaran, Ranjit K. Elliott, Lindsay S. Henderson, John C. Neradilek, Moni B. Moyer, Nicolas A. Ashcraft, Kristine C. |
| AuthorAffiliation | 1 Department of Pharmacy Practice, Harding University College of Pharmacy / Unity Health – White County Medical Center, Searcy, Arkansas, United States of America 2 Unity Health - White County Medical Center, Searcy, Arkansas, United States of America 3 The Mountain-Whisper-Light Statistics, Seattle, Washington, United States of America University Hospital Jena, GERMANY 4 Clinical Pharmacogenomics Division, Genelex Corporation, Seattle, Washington, United States of America |
| AuthorAffiliation_xml | – name: University Hospital Jena, GERMANY – name: 1 Department of Pharmacy Practice, Harding University College of Pharmacy / Unity Health – White County Medical Center, Searcy, Arkansas, United States of America – name: 3 The Mountain-Whisper-Light Statistics, Seattle, Washington, United States of America – name: 4 Clinical Pharmacogenomics Division, Genelex Corporation, Seattle, Washington, United States of America – name: 2 Unity Health - White County Medical Center, Searcy, Arkansas, United States of America |
| Author_xml | – sequence: 1 givenname: Lindsay S. orcidid: 0000-0002-5564-5397 surname: Elliott fullname: Elliott, Lindsay S. – sequence: 2 givenname: John C. surname: Henderson fullname: Henderson, John C. – sequence: 3 givenname: Moni B. surname: Neradilek fullname: Neradilek, Moni B. – sequence: 4 givenname: Nicolas A. surname: Moyer fullname: Moyer, Nicolas A. – sequence: 5 givenname: Kristine C. surname: Ashcraft fullname: Ashcraft, Kristine C. – sequence: 6 givenname: Ranjit K. surname: Thirumaran fullname: Thirumaran, Ranjit K. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28151991$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk9tq3DAURU1JaS7tH5RWUCjtw0ylkWxLeSiE0EsgEOjtVWjkoxkF2XIlOW36Rf3MyhlPyYRQih9s5LW3dLbOOSz2Ot9BUTwleE5oTd5c-iF0ys37vDzHpMYClw-KAyLoYlYtMN279b1fHMZ4iXFJeVU9KvYXnJRECHJQ_D51trNaOWTbXumEvEH9WoVWab-CDpLVqA_e2Iyt0A-b1kghvdU0oG20vkNx6HsfEkreZ6cO9d5dTzbXaO1bQGtQLot7lSx0KR6jk9E39qCTvQLUW-cTCqprfGt_QYO071LwzuXPFKxyj4uHRrkIT6b3UfH1_bsvpx9n5xcfzk5Pzme6XpRpthRlpRmHCkiJNZjF0hAqDG5ywTUYxU2luVLKsAWwipGGE25MqWljODVVTY-K5xvf3vkop5CjJLxiDDPBRCbONkTj1aXsg21VuJZeWXmz4MNKqpBzcyDxkoilYNAQTBkvay7yASilNaZKVxXPXm-n3YZlC43O0QTldkx3_3R2LVf-SpYLLkpaZYNXk0Hw3weISbY2anBOdeCHm3NzyvDYBEfFizvo_dVN1ErlAmxnfN5Xj6byhNWiLkVVskzN76Hy00Br89VBbhjYFbzeEYzXCz_TSg0xyrPPn_6fvfi2y768xW6aLHo3pNyVcRd8djvpvxFvRyEDxxtA57aMAYzUNqnRJ5dmnSRYjnO3DU2Ocyenuctidke89f-n7A_NFjXU |
| CitedBy_id | crossref_primary_10_3390_jcm9061801 crossref_primary_10_1016_j_sapharm_2022_04_004 crossref_primary_10_1016_S0140_6736_22_01841_4 crossref_primary_10_3389_fphar_2023_1178715 crossref_primary_10_1111_bcp_15956 crossref_primary_10_2217_pgs_2018_0099 crossref_primary_10_3389_fgene_2021_698148 crossref_primary_10_1016_j_cll_2022_09_012 crossref_primary_10_1136_bmjopen_2024_087064 crossref_primary_10_1200_PO_18_00011 crossref_primary_10_1016_j_compbiomed_2023_107329 crossref_primary_10_1111_ctr_14037 crossref_primary_10_2217_pgs_2017_0093 crossref_primary_10_1016_j_pnpbp_2018_05_007 crossref_primary_10_1002_cpt_3297 crossref_primary_10_1007_s40142_018_0136_y crossref_primary_10_1080_14740338_2019_1571037 crossref_primary_10_1017_pcm_2022_3 crossref_primary_10_1186_s12911_020_01376_8 crossref_primary_10_3390_jpm12020161 crossref_primary_10_30773_pi_2019_06_16 crossref_primary_10_1093_ageing_afac191 crossref_primary_10_1111_cts_12986 crossref_primary_10_1371_journal_pone_0220071 crossref_primary_10_1016_j_sapharm_2021_08_009 crossref_primary_10_1016_j_jamda_2020_04_009 crossref_primary_10_1097_FPC_0000000000000405 crossref_primary_10_1038_s41431_019_0454_x crossref_primary_10_1080_23808993_2022_2028548 crossref_primary_10_2217_pgs_2020_0077 crossref_primary_10_1002_cpt_1489 crossref_primary_10_1080_14740338_2018_1546841 crossref_primary_10_3390_ijms19061707 crossref_primary_10_1111_jgs_17041 crossref_primary_10_1007_s40122_017_0069_2 crossref_primary_10_1002_jgf2_464 crossref_primary_10_25557_2073_7998_2019_01_13_24 crossref_primary_10_3390_jpm12081297 crossref_primary_10_3390_pharmaceutics14010160 crossref_primary_10_15446_rsap_v21n2_76678 crossref_primary_10_1080_14622416_2025_2466413 crossref_primary_10_3390_cancers12071951 crossref_primary_10_1038_s41397_024_00350_1 crossref_primary_10_9758_cpn_2020_18_1_1 crossref_primary_10_2217_pgs_2019_0198 crossref_primary_10_2217_pgs_2020_0066 crossref_primary_10_1080_03602532_2021_1909613 crossref_primary_10_2217_pgs_2019_0194 crossref_primary_10_2217_pgs_2023_0185 crossref_primary_10_3390_geriatrics8050084 crossref_primary_10_2217_pgs_2019_0197 crossref_primary_10_1007_s00439_021_02369_x crossref_primary_10_1038_s41397_025_00362_5 crossref_primary_10_1007_s40264_021_01068_w crossref_primary_10_1038_s41397_020_0148_3 crossref_primary_10_1177_0706743720971950 crossref_primary_10_1161_CIRCRESAHA_117_310782 crossref_primary_10_1016_j_neulet_2018_06_020 crossref_primary_10_1080_17425255_2021_1867105 crossref_primary_10_2147_PGPM_S348851 crossref_primary_10_1089_jpm_2025_0038 crossref_primary_10_1002_ajmg_c_31866 crossref_primary_10_1093_qjmed_hcae200 crossref_primary_10_3390_jpm12121972 crossref_primary_10_3390_pharmacy11050144 crossref_primary_10_1080_17476348_2024_2329612 crossref_primary_10_1038_s41397_021_00260_6 crossref_primary_10_2147_PGPM_S415259 crossref_primary_10_3390_jpm11121242 crossref_primary_10_1002_jac5_1570 crossref_primary_10_3390_ijms222413302 crossref_primary_10_1016_j_jpsychires_2020_05_002 crossref_primary_10_1016_j_jgo_2020_06_013 crossref_primary_10_1038_s41397_021_00224_w crossref_primary_10_18553_jmcp_2018_24_12_1250 crossref_primary_10_1186_s12916_019_1342_5 crossref_primary_10_3928_19404921_20210428_01 crossref_primary_10_1002_hup_2677 crossref_primary_10_1016_j_jagp_2017_05_012 crossref_primary_10_1097_01_NPR_0000580780_66980_85 crossref_primary_10_1002_cpt_1049 crossref_primary_10_1111_bcpt_13336 crossref_primary_10_1038_s41397_024_00326_1 crossref_primary_10_3390_genes10060416 crossref_primary_10_3390_pharmacy13010014 crossref_primary_10_1016_j_jagp_2020_05_005 crossref_primary_10_1093_ajhp_zxy079 crossref_primary_10_3389_fpsyt_2019_00690 crossref_primary_10_1124_pharmrev_123_000750 crossref_primary_10_1176_appi_focus_19107 crossref_primary_10_2196_32902 crossref_primary_10_1097_YPG_0000000000000230 crossref_primary_10_1093_milmed_usab098 crossref_primary_10_3389_fphar_2024_1349203 crossref_primary_10_1007_s00213_017_4622_9 crossref_primary_10_1016_j_jagp_2020_03_003 crossref_primary_10_1002_14651858_CD001096_pub2 crossref_primary_10_1016_j_yamp_2020_07_012 crossref_primary_10_1111_joim_13330 crossref_primary_10_36303_SAGP_0070 crossref_primary_10_1097_FPC_0000000000000346 crossref_primary_10_1093_bib_bbz038 crossref_primary_10_1016_S0140_6736_22_02461_8 |
| Cites_doi | 10.1056/NEJMsa1103053 10.1186/1471-2288-13-99 10.1186/1745-6215-15-139 10.1016/j.pharmthera.2012.12.007 10.2217/pgs.14.6 10.1377/hlthaff.27.3.759 10.1007/s00228-015-1965-1 10.1007/BF03319099 10.1016/j.amjopharm.2007.12.002 10.2146/ajhp150273 10.1002/cpt.113 10.1038/clpt.2011.185 10.1377/hlthaff.W5.152 10.1001/jama.279.15.1200 10.1016/S1543-5946(03)90004-3 10.1001/jama.296.15.1858 10.1001/jamapsychiatry.2014.436 10.1126/science.286.5439.487 10.3111/13696998.2015.1110160 10.1001/jama.2008.892 10.1345/aph.1Q529 10.1038/tpj.2015.39 10.1056/NEJMra032424 10.1002/cpt.147 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2017 Public Library of Science 2017 Elliott et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2017 Elliott et al 2017 Elliott et al |
| Copyright_xml | – notice: COPYRIGHT 2017 Public Library of Science – notice: 2017 Elliott et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2017 Elliott et al 2017 Elliott et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 5PM DOA |
| DOI | 10.1371/journal.pone.0170905 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database (Proquest) Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database (Proquest) Nursing & Allied Health Premium Advanced Technologies & Aerospace Collection ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database (Proquest) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) |
| DatabaseTitleList | MEDLINE Genetics Abstracts Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Pharmacogenetic profiling and polypharmacy home health patients |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1864404949 oai_doaj_org_article_0b19b94ed103485789a8f333703ac668 PMC5289536 4311955851 A479759654 28151991 10_1371_journal_pone_0170905 |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | United States--US Arkansas |
| GeographicLocations_xml | – name: Arkansas – name: United States--US |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 ESTFP PUEGO 5PM - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c725t-b956c48e6e150cef2bf139f0d1517efa8f6c8aaaf42e4641d818ff5c3df83f673 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Thu Nov 25 14:37:17 EST 2021 Wed Aug 27 01:31:45 EDT 2025 Thu Aug 21 18:12:20 EDT 2025 Mon Sep 08 10:51:03 EDT 2025 Fri Jul 25 10:15:02 EDT 2025 Tue Jun 17 20:47:15 EDT 2025 Tue Jun 10 20:31:09 EDT 2025 Fri Jun 27 03:46:17 EDT 2025 Fri Jun 27 05:09:31 EDT 2025 Thu May 22 21:23:41 EDT 2025 Wed Feb 19 02:34:49 EST 2025 Tue Jul 01 03:11:47 EDT 2025 Thu Apr 24 22:58:13 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c725t-b956c48e6e150cef2bf139f0d1517efa8f6c8aaaf42e4641d818ff5c3df83f673 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 Conceptualization: LSE JCH KCA.Data curation: LSE NAM.Formal analysis: MBN NAM.Funding acquisition: LSE MBN.Investigation: LSE.Methodology: LSE JCH KCA MBN.Project administration: LSE KCA.Supervision: LSE RKT.Validation: LSE MBN NAM.Visualization: LSE MBN NAM RKT.Writing – original draft: LSE JCH MBN NAM KCA RKT.Writing – review & editing: LSE JCH MBN NAM KCA RKT. Competing Interests: We have the following interests: NAM, KCA and RKT are employees and potential equity holders of Genelex corporation. MBN is an employee of The Mountain-Whisper-Light Statistics. Genelex provided the support in the form of compensation for time for authors LSE and MBN. YouScript® is a clinical decision support tool with issued and pending patents. NAM is listed as an inventor on provisional patent application US 20160004838/WO 2016003514 A1, which relates to the drug interaction algorithm used by YouScript®. There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. |
| ORCID | 0000-0002-5564-5397 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0170905 |
| PMID | 28151991 |
| PQID | 1864404949 |
| PQPubID | 1436336 |
| PageCount | e0170905 |
| ParticipantIDs | plos_journals_1864404949 doaj_primary_oai_doaj_org_article_0b19b94ed103485789a8f333703ac668 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5289536 proquest_miscellaneous_1868340620 proquest_journals_1864404949 gale_infotracmisc_A479759654 gale_infotracacademiconefile_A479759654 gale_incontextgauss_ISR_A479759654 gale_incontextgauss_IOV_A479759654 gale_healthsolutions_A479759654 pubmed_primary_28151991 crossref_citationtrail_10_1371_journal_pone_0170905 crossref_primary_10_1371_journal_pone_0170905 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-02-02 |
| PublicationDateYYYYMMDD | 2017-02-02 |
| PublicationDate_xml | – month: 02 year: 2017 text: 2017-02-02 day: 02 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2017 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | WE Evans (ref5) 1999; 286 ref34 ref33 UM Zanger (ref4) 2013; 138 WJ Azhar Gohar (ref18) 2016; 4 ref1 DG Safran (ref10) 2005; Suppl Web Exclusives LM Hampton (ref3) 2014; 71 KA Birdwell (ref23) 2015; 98 ref19 BC Kahan (ref31) 2013; 13 O Alagoz (ref35) 2016; 16 (ref26) 2010 J Fagerness (ref14) 2014; 20 D Brixner (ref17) 2016; 19 M Cardelli (ref7) 2012; 35 DS Budnitz (ref30) 2006; 296 GR Wilkinson (ref6) 2005; 352 ref25 ref20 JA Johnson (ref24) 2011; 90 BT Hocum (ref16) 2016; 73 JK Hicks (ref22) 2015; 98 P Lisbeth (ref28) 2016; 72 ER Hajjar (ref27) 2003; 1 KC Sikdar (ref13) 2012; 46 J Lazarou (ref12) 1998; 279 BC Kahan (ref32) 2014; 15 DS Budnitz (ref11) 2011; 365 ER Hajjar (ref9) 2007; 5 DM Berwick (ref36) 2008; 27 A Gaedigk (ref29) 2016 DM Qato (ref8) 2008; 300 CD Hepler (ref2) 1990; 47 KE Caudle (ref21) 2016 P Verbeurgt (ref15) 2014; 15 |
| References_xml | – volume: 365 start-page: 2002 issue: 21 year: 2011 ident: ref11 article-title: Emergency hospitalizations for adverse drug events in older Americans publication-title: N Engl J Med doi: 10.1056/NEJMsa1103053 – volume: 13 start-page: 99 year: 2013 ident: ref31 article-title: Adjusting for multiple prognostic factors in the analysis of randomised trials publication-title: BMC Med Res Methodol doi: 10.1186/1471-2288-13-99 – volume: 15 start-page: 139 year: 2014 ident: ref32 article-title: The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies publication-title: Trials doi: 10.1186/1745-6215-15-139 – ident: ref1 – volume: 138 start-page: 103 issue: 1 year: 2013 ident: ref4 article-title: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2012.12.007 – volume: 15 start-page: 655 issue: 5 year: 2014 ident: ref15 article-title: How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping publication-title: Pharmacogenomics doi: 10.2217/pgs.14.6 – year: 2016 ident: ref21 article-title: Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) publication-title: Genet Med – ident: ref20 – volume: 27 start-page: 759 issue: 3 year: 2008 ident: ref36 article-title: The triple aim: care, health, and cost publication-title: Health Affairs (Millwood) doi: 10.1377/hlthaff.27.3.759 – volume: 72 start-page: 175 issue: 2 year: 2016 ident: ref28 article-title: Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-015-1965-1 – volume: 35 start-page: 3 issue: Suppl 1 year: 2012 ident: ref7 article-title: A review of pharmacogenetics of adverse drug reactions in elderly people publication-title: Drug Saf doi: 10.1007/BF03319099 – ident: ref25 – volume: 4 issue: 1 year: 2016 ident: ref18 article-title: Differences in Medicare Quality Measures among Nursing Homes after Pharmacogenetic Testing publication-title: Journal of Research and Development – ident: ref19 – volume: 5 start-page: 345 issue: 4 year: 2007 ident: ref9 article-title: Polypharmacy in elderly patients publication-title: Am J Geriatr Pharmacother doi: 10.1016/j.amjopharm.2007.12.002 – volume: 73 start-page: 61 issue: 2 year: 2016 ident: ref16 article-title: Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing publication-title: Am J Health Syst Pharm doi: 10.2146/ajhp150273 – volume: 98 start-page: 19 issue: 1 year: 2015 ident: ref23 article-title: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.113 – volume: 90 start-page: 625 issue: 4 year: 2011 ident: ref24 article-title: Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2011.185 – ident: ref34 – volume: Suppl Web Exclusives start-page: W5-152 year: 2005 ident: ref10 article-title: Prescription drug coverage and seniors: findings from a 2003 national survey publication-title: Health Aff (Millwood) doi: 10.1377/hlthaff.W5.152 – volume: 279 start-page: 1200 issue: 15 year: 1998 ident: ref12 article-title: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies publication-title: JAMA doi: 10.1001/jama.279.15.1200 – volume: 1 start-page: 82 issue: 2 year: 2003 ident: ref27 article-title: Adverse drug reaction risk factors in older outpatients publication-title: Am J Geriatr Pharmacother doi: 10.1016/S1543-5946(03)90004-3 – year: 2016 ident: ref29 article-title: Prediction of CYP2D6 phenotype from genotype across world populations publication-title: Genet Med – volume: 296 start-page: 1858 issue: 15 year: 2006 ident: ref30 article-title: National surveillance of emergency department visits for outpatient adverse drug events publication-title: JAMA doi: 10.1001/jama.296.15.1858 – volume: 71 start-page: 1006 issue: 9 year: 2014 ident: ref3 article-title: Emergency department visits by adults for psychiatric medication adverse events publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2014.436 – volume: 286 start-page: 487 issue: 5439 year: 1999 ident: ref5 article-title: Pharmacogenomics: translating functional genomics into rational therapeutics publication-title: Science doi: 10.1126/science.286.5439.487 – volume: 19 start-page: 213 issue: 3 year: 2016 ident: ref17 article-title: The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy publication-title: J Med Econ doi: 10.3111/13696998.2015.1110160 – volume: 300 start-page: 2867 issue: 24 year: 2008 ident: ref8 article-title: Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States publication-title: JAMA doi: 10.1001/jama.2008.892 – volume: 20 start-page: e146 issue: 5 year: 2014 ident: ref14 article-title: Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings publication-title: Am J Manag Care – year: 2010 ident: ref26 article-title: Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing and Labeling – volume: 46 start-page: 960 issue: 7–8 year: 2012 ident: ref13 article-title: Adverse drug reactions in elderly hospitalized patients: a 12-year population-based retrospective cohort study publication-title: Ann Pharmacother doi: 10.1345/aph.1Q529 – volume: 16 start-page: 129 issue: 2 year: 2016 ident: ref35 article-title: Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions publication-title: Pharmacogenomics J doi: 10.1038/tpj.2015.39 – volume: 352 start-page: 2211 issue: 21 year: 2005 ident: ref6 article-title: Drug metabolism and variability among patients in drug response publication-title: N Engl J Med doi: 10.1056/NEJMra032424 – volume: 47 start-page: 533 issue: 3 year: 1990 ident: ref2 article-title: Opportunities and responsibilities in pharmaceutical care publication-title: Am J Hosp Pharm – volume: 98 start-page: 127 issue: 2 year: 2015 ident: ref22 article-title: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.147 – ident: ref33 |
| SSID | ssj0053866 |
| Score | 2.5396101 |
| Snippet | In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing... Background In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on... BackgroundIn polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on... Background In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0170905 |
| SubjectTerms | Acceptance tests Aged Analysis Biology and Life Sciences Clinical trials Confidence intervals Consortia Cytochrome Decision making Decision support systems Decision Support Systems, Clinical Drug dosages Drug stores Drug-Related Side Effects and Adverse Reactions - genetics Drug-Related Side Effects and Adverse Reactions - prevention & control Drugs Emergency medical services FDA approval Female Gene Expression Profiling Genes Genotype & phenotype Health Health care Home Care Agencies Home Care Services Home health care Hospitalization Hospitals Humans Information systems Kidney diseases Labeling Male Management Medicare Medicine and Health Sciences Middle Aged Older people Outcome Assessment (Health Care) Patients Pharmacists Pharmacogenomic Variants Pharmacology Pharmacy Polypharmacy Population Practice Prescription drugs Prescriptions (Drugs) Profiling Prospective Studies Quality of life R&D Randomization Research & development Resource management Resource utilization Therapy Trends |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELbQnrggyquBUgxCAg5p87Adm9uCqAoSIAFFvUWOY7crpUlEdg_tL-JnMpM40QZVKgduq_XE2p2XP-_OfEPIS2YBNBgVh1JzFTJh47CwpQ55KbTj0sXCYaPw5y_i-IR9OuWnW6O-sCZsoAceFHcYFbEqFLNlHKVMgn8pLV2apuCp2gjRt_lGKhovU0MOhigWwjfKpVl86O1y0Da1PUDGGIXj6rYOop6vf8rKi7Zquusg59-Vk1tH0dFdcsdjSLocPvsOuWXre2THR2lHX3sq6Tf3yW9P-1nRoRuSNo62nqwaPAcbGOkwtRtOMIq_yVJNx2ZJWvr5O7TbtAjT6bppYKeatk116be5pOfNhaVDOyX1LK3dW7rEfcc2TtquqmZN4Vgsm4vVlS2pr5Cv4GU_N-QBOTn68OP9cehnM4QmS_g6LOBeZZi0YFweGeuSwgGWdFEJCCKzDmwkjNRaO5ZYJlhcAjBwjpu0dDJ1IksfkkUN1tglVFsOa5arpBDMxLyApJJYzmUZK5MUJiDpaKjceOJynJ9R5f2_cRlcYAa952je3Js3IOH0VDsQd9wg_w59YJJF2u3-DXDG3DtjfpMzBuQZelA-KH1KHvmSZSrjSnAWkBe9BFJv1Fjbc6Y3XZd__PrzH4S-f5sJvfJCrgF1GO37KeA7IaXXTHJvJgkJxMyWd9HfR610eSwFskYqpuDJMQauX34-LeOmWK9X22bTy8gUsGISBeTREDKTZhMJPgLXkoBks2CaqX6-Uq_Oe-ZznkgsN3j8P2z1hNxOEKJhBX6yRxbrXxv7FADmutjvc8kfxQ59WQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwELXK9sIFUb6aUsAgJOCQdpPYjoOE0Ba1KkgsqFDUW-Q4drvSNg7N7qH8In4mM4mzNKgCbqt4Ym1mPM_jZOYNIc-ZgaBBZ1EoFc9CJkwUFqZUIS-FslzaSFgsFP44FYfH7MMJP1kj074WBtMqe0xsgbp0Gt-R70ZSIJVdxrK39fcQu0bh19W-hYbyrRXKNy3F2A2yDpDMxyOyvrc__XzUYzN4txC-gC5Jo11vr53aVWYHmWQybGN3ZYNqefxXaD2q5665LhT9M6PyyhZ1cJvc8rElnXSLYYOsmeoO2fDe29CXnmL61V3y09OBzmlXJUmdpbUnsYYVhYWNtOvmDTsbxXe1VNG-iJKWvi8PbZY1hu904RzMVNHazS_9NJf0zJ0b2pVZUs_e2rymE5y3L--k9WzuFhS2y9Kdz36YkvrM-Tn8bPuJ3CPHB_tf3x2GvmdDqNOYL8ICzluaSQNG52NtbFxYiDHtuITIIjVWSSu0VEpZFhsmWFRCwGAt10lpZWJFmtwnowqssUmoMmBJa3gWF4LpiBcANrHhXJZRpuNCByTpDZVrT2iOfTXmefuVLoWDTaf3HM2be_MGJFzdVXeEHv-Q38M1sJJFOu72grs4zb135-MiyoqMmTIaJ0wCCGbwoEmSAJwqLYQMyBNcQXmn9BWo5BOWZinPBGcBedZKICVHhTk_p2rZNPn7T9_-Q-jL0UDohReyDtShla-zgGdCqq-B5PZAEoBFD4Y3cb33Wmny3y4Id_Y-cP3w09UwTop5fJVxy1ZGJhBDxuOAPOhcZqXZWMIageNKQNKBMw1UPxypZmctIzqPJaYhbP39bz0kN2MMyjDnPt4mo8XF0jyCkHJRPPY48Qua13zK priority: 102 providerName: ProQuest |
| Title | Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28151991 https://www.proquest.com/docview/1864404949 https://www.proquest.com/docview/1868340620 https://pubmed.ncbi.nlm.nih.gov/PMC5289536 https://doaj.org/article/0b19b94ed103485789a8f333703ac668 http://dx.doi.org/10.1371/journal.pone.0170905 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fb9MwELdG98ILYvxbYRSDkICHVE1iOw4SQt20MpAYaFC0tyhx7K1SloSmlSifiI_JXeJEBBWxl6jqnS3lfHc-x3e_I-Q50xA0qNB1ZMxDhwntOolOY4enIjZcGlcYLBT-eCpO5uzDOT_fIW3PVivAauvRDvtJzZfZ-Mf3zVsw-Dd114bAbQeNyyLXY8SDCRHUdLe-McJkPtbdK4B117eXGLU4wpv4tpjuX7P0Nqsa07_z3IMyK6ptYenf2ZV_bFez2-SWjTPptFGMPbKj8ztkz1pyRV9auOlXd8kvCw2a0aZikhaGlhbQGrQLixxp09kbdjmK321pTNuCSpraHj20WpcoRboqCpgpp2WRbew0G3pZXGnalFxSi-RavaZTnLct9aTlIitWFLbOtLha_NQptVn0Gfyse4vcI_PZ8dejE8f2b3BU4PGVk8DZSzGpQQH4RGnjJQbiTTNJIcoItImlEUrGcWyYp5lgbgrBgzFc-amRvhGBf58McliNfUJjzYGmeeglgimXJ-B4PM25TN1QeYkaEr9dqEhZcHPssZFF9Y1dAIecRu4RLm9kl3dInG5U2YB7_If_EHWg40Vo7vqPYnkRWUuPJokbJiHTqTvxmQSHGMKL-r4PrjVWQsgheYIaFDVC7xxMNGVBGPBQcDYkz2oOhOfIMf_nIl5XVfT-07drMH056zG9sEymAHGo2NZcwDsh7FeP86DHCU5G9cj7qO-tVKrIlQKRJUMWwsjWBraTn3ZknBRz-nJdrGse6UM86U2G5EFjMp1kPQk6AkeXIQl6xtQTfZ-SLy5rdHTuSUxJeHgdIT4iNz0M0zAL3zsgg9VyrR9DkLlKRuRGcB7AUx65-Jy9G5Hdw-PTz2ej-rPNqPYrvwHX5YUT |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbK9gAXRPnrQqEGgYBD2o1jOwlShVpo1dIfUGlRb8Fx7HalbRKaXaHyRDwFz8ZM4iwNqoBLb6v1xErG42_Gycw3hDzjBoIGHftepETscWl8LzWZ8kQmlRWR9aXFQuHdPbl5yN8fiaMZ8rOthcG0yhYTa6DOCo3vyJf9SCKVXczjN-VXD7tG4dfVtoWGcq0VspWaYswVdmyb829whKtWtt7Bej9nbGP94O2m57oMeDpkYuylcELQPDJwm2KgjWWphajIDjLwhaGxKrJSR0opy5nhkvsZuDhrhQ4yGwVWhgHMe43McnyB0iOza-t7H_dbXwBoIqUr2AtCf9nZx1JZ5GYJmWtibJt3wSHWfQOm3qFXjorqstD3zwzOCy5x4xa56WJZutoY3xyZMfltMufQoqIvHaX1qzvkh6MfHdGmKpMWlpaONBssGAspadM9HDwpxXfDVNG2aJNmrg8QrSYlHhfouChgppyWxejcTXNOT4pTQ5uyTurYYqvXdBXnbctJaTkcFWMK7jkrToffTUZdpv4Iftb9S-6SwytZvXukl8NqzBOqDFiONSJmqeTaFymAGzNCRJkfa5bqPgnahUq0I1DHPh6jpP4qGMJBqtF7gsubuOXtE296VdkQiPxDfg1tYCqL9N_1H8XZceLQJBmkfpzG3GT-IOARgG4MDxoEAcC30lJGfbKIFpQ0Sp-CWLLKwzgUsRS8T57WEkgBkmOO0bGaVFWy9eHzfwh92u8IvXBCtgB1aOXqOuCZkFqsI7nQkQQg053hebT3VitV8nvLw5XtHrh8-Ml0GCfFvMHcFJNaJgogZmWDPrnfbJmpZlkENgLHoz4JO5upo_ruSD48qRnYBYsw7eHB329rkVzfPNjdSXa29rYfkhsMA0LM92cLpDc-m5hHEM6O08cOMyj5ctUw9QspG7sn |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbKIiEuiPLXhUINAgGHtJvEdhwkhAqlaikURCnaW0gcu11pG4dmV6g8Ec_A0zGTOKFBFXDpbbWeWMnM-JuZZH4Iecg0OA0q9j2Z8thjQvtepvPU47lIDZfGFwYLhd_tiq199mbMxwvkZ1sLg2mVLSbWQJ1bhe_I13wpsJVdzOI149IiPmxsvii_ejhBCr-0tuM0GhXZ0SffIHyrnm9vgKwfBcHm60-vtjw3YcBTUcBnXgbRgWJSwy3ykdImyAx4RGaUgx2MtEmlEUqmaWpYoJlgfg7mzRiuwtzI0IgohH0vkItRCLcGZykad8Ee4IgQrlQvjPw1pxmrpS30KvasiXFg3ilTWE8M6OzCoJza6iyn98_czVPGcPMqueK8WLreqN0iWdDFNbLocKKiT1wz66fXyQ_XeHRKm3pMag0tXbts0F0soaTN3HCwoRTfCtOUtuWaNHcTgGg1LzFQoDNrYaeClnZ64rY5oYf2SNOmoJO6PrHVM7qO-7aFpLScTO2MgmHO7dHku86py9Gfws96cskNsn8usrtJBgVIY4nQVHNY0zwOMsGUzzOAtUBzLnM_VkGmhiRsBZUo1zodJ3hMk_p7YAQhVMP3BMWbOPEOidddVTatQ_5B_xJ1oKPFxt_1H_b4IHE4kowyP85ipnN_FDIJcBvDg4ZhCMCdKiHkkKygBiUN0zv4StZZFEc8FpwNyYOaApt_FHiMDtJ5VSXb7z__B9Hexx7RY0dkLLBDpa6iA54Jm4r1KJd7lABhqre8hPrecqVKfh92uLI9A2cv3--WcVPMGCy0ndc0MgRvNRgNya3myHScDSToCARGQxL1DlOP9f2VYnJY917ngcSEh9t_v60VcgnAKXm7vbtzh1wO0BOsE_2XyWB2PNd3wY-dZfdqwKDky3kj1C8wSrjC |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+impact+of+pharmacogenetic+profiling+with+a+clinical+decision+support+tool+in+polypharmacy+home+health+patients%3A+A+prospective+pilot+randomized+controlled+trial&rft.jtitle=PloS+one&rft.au=Elliott%2C+Lindsay+S&rft.au=Henderson%2C+John+C&rft.au=Neradilek%2C+Moni+B&rft.au=Moyer%2C+Nicolas+A&rft.date=2017-02-02&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=12&rft.issue=2&rft.spage=e0170905&rft_id=info:doi/10.1371%2Fjournal.pone.0170905&rft.externalDBID=IOV&rft.externalDocID=A479759654 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |